Medicinal Psychedelics Study, AI Art. December 9, 2022, Part 2 episode artwork

EPISODE · Dec 9, 2022 · 46 MIN

Medicinal Psychedelics Study, AI Art. December 9, 2022, Part 2

from Science Friday · host WNYC Studios, Science Friday

The Science Behind The Psychedelics Boom There’s been an explosion of new research into therapeutic uses for psychedelics. This includes drugs like psilocybin, the hallucinogenic chemical found in “magic mushrooms,” and ketamine—which was originally used as an anesthetic, and later became a popular party drug also known as “special K.” Esketamine, a form of ketamine, was approved by the FDA in 2019 for use in treatment resistant depression. And just last month Colorado residents voted to legalize medicinal use of psilocybin. Following on the heels of Oregon’s legalization in 2020, which is now in the process of being implemented. A recent study published in the New England Journal of Medicine showed promising results in using psilocybin to help patients with treatment-resistant depression. About a third of those who received the highest dose were in remission 3 weeks later. This was the largest look at psilocybin’s effect on depression to date, involving 233 participants across ten countries in Europe. Ira talks with Dr. Steve Levine, senior vice president of patient access and medical affairs at COMPASS Pathways, the company that funded the study. Later, Ira takes a closer look into the latest psychedelic research and takes listener calls with Dr. Gerard Sanacora, professor of psychiatry and director of the Yale Depression Research Program at the Yale School of Medicine, and Dr. Alissa Bazinet, Clinical Psychologist, Co-Founder and Director of Research and Development at the Sequoia Center, and Associate Director of the Social Neuroscience and Psychotherapy Lab at Oregon Health and Science University.     How Will AI Image Generators Affect Artists? Back in August, controversy erupted around the winning submission of the Colorado State Fair’s art content. The winning painting wasn’t made by a human, but by an artificial intelligence app called Midjourney, which takes text prompts and turns them into striking imagery, with the help of a neural network and an enormous database of images. AI-based text-to-image generators have been around for years, but their outputs were rudimentary and rough. The State Fair work showed this technology had taken a giant leap forward in its sophistication. Realistic, near-instant image generation was suddenly here—and reactions were just as potent as their creations. Tech enthusiasts lauded the achievement, while artists were largely concerned and critical. If anyone could make a painting in just a few seconds, why would someone need to commission an artist to produce an illustration, or even bother spending years learning art at all? Read the rest on sciencefriday.com. Transcripts for each segment will be available the week after the show airs on sciencefriday.com.   Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that’s keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode metadata supplied by the publisher feed · Published Dec 9, 2022

Embed this episode

NOW PLAYING

Medicinal Psychedelics Study, AI Art. December 9, 2022, Part 2

0:00 46:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Science Friday?

This episode is 46 minutes long.

When was this Science Friday episode published?

This episode was published on December 9, 2022.

Can I download this Science Friday episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!